Skip to main content
. 2024 Feb 20;18(3):475–478. doi: 10.1002/1878-0261.13606

Fig. 1.

Fig. 1

Clinically relevant therapies show a target bias that can be exploited by AML LSCs via lineage plasticity to achieve resistance.